UBS lowered the firm’s price target on AMN Healthcare (AMN) to $25.50 from $30 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN:
- AMN Healthcare Services: Strong Performance and Optimistic Outlook Justify Buy Rating
- AMN Healthcare’s Mixed Earnings Call: Achievements and Challenges
- AMN Healthcare Services: Stabilization Amidst Challenges and Cautious Hold Rating
- AMN Healthcare Reports Q1 2025 Financial Results
- AMN Healthcare sees Q2 revenue $645M-$660M, consensus $648.92M